Guo Jiazheng, Lu Jiansheng, Du Peng, Cheng Kexuan, Lei Chao, Jiang Yujia, Peng Meiling, Li Yating, Sun Kaiyue, Xu Changyan, Yu Yunzhou, Gao Chen, Kang Qinglin, Zhang Yixiao, Wang Rong, Yang Zhixin
Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China.
Curr Issues Mol Biol. 2025 Feb 21;47(3):140. doi: 10.3390/cimb47030140.
Dengue virus (DENV) is a major public health threat in the tropical and subtropical regions of the world. Climate change resulting from global warming is further expanding DENV-endemic areas, adversely affecting public life and health. Despite this, no specific drug against DENV has been developed so far. Vaccines and neutralizing antibodies are the chief preventive and therapeutic tools for managing pathogenic infections. The present study describes the development of a novel fluorescence reduction neutralization test (FRNT) for evaluating the neutralizing activity of antibodies against DENV. This FRNT allows rapid antibody screening. In addition, we calculated the FRNT to indicate the neutralizing ability of the antibodies. In contrast to the conventional plaque reduction neutralization assay, the FRNT has a shorter experimental cycle, a simpler operation, and greater objectivity, which can greatly accelerate the research and development process of vaccines and antibodies against DENV.
登革病毒（DENV）是世界热带和亚热带地区的主要公共卫生威胁。全球变暖导致的气候变化正在进一步扩大登革病毒流行地区，对公众生活和健康产生不利影响。尽管如此，迄今为止尚未开发出针对登革病毒的特效药物。疫苗和中和抗体是管理致病性感染的主要预防和治疗工具。本研究描述了一种新型荧光减少中和试验（FRNT）的开发，用于评估针对登革病毒的抗体的中和活性。这种FRNT允许快速抗体筛选。此外，我们计算了FRNT以表明抗体的中和能力。与传统的蚀斑减少中和试验相比，FRNT具有更短的实验周期、更简单的操作和更高的客观性，这可以大大加速针对登革病毒的疫苗和抗体的研发进程。
